Hepatitis C Treatment in United States Prisons Prevents Transmission and is Cost-Saving for the Society

被引：0
|
作者：
Chhatwal, Jaapreet [1 ,2 ]
Li, Kan [3 ]
He, Tianhua [4 ]
Roberts, Mark S. [5 ]
Ayer, Turgay [6 ]
Samur, Sumeyye [1 ,2 ]
Grefenstette, John [5 ]
Spaulding, Anne C. [7 ]
机构：
[1] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[4] Tsinghua Univ, Sch Med, Beijing, Peoples R China
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Georgia Inst Technol, Atlanta, GA 30332 USA
[7] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1723
引用
收藏
页码：851A / 852A
页数：2
相关论文
共 50 条
  • [1] Going private: Are private prisons cost-saving options for states?
    White, Weston
    Pena, Anita Alves
    Weiler, Stephan
    [J]. GROWTH AND CHANGE, 2020, 51 (03) : 1000 - 1016
  • [2] Elimination of hepatitis C in Brazil is cost-saving
    Benzaken, A.
    Girade, R.
    Razavi, H.
    Schmelzer, J.
    Ferraz, M. L.
    Ferreira, P. A.
    Pessoa, M. G.
    Martinelli, A.
    Catapan, E.
    Souto, F.
    Correa, M. C. M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 157 - 157
  • [3] Treating Hepatitis C in the Prison Population Is Cost-Saving
    Tan, Jennifer A.
    Joseph, Tom A.
    Saab, Sammy
    [J]. HEPATOLOGY, 2008, 48 (05) : 1387 - 1395
  • [4] HEPATITIS C TREATMENT AS PREVENTION: FOCUSING ON UNITED STATES PRISONS
    Chhatwal, J.
    Li, K.
    He, T.
    Roberts, M. S.
    Ayer, T.
    Samur, S. S.
    Grefenstette, J. J.
    Spaulding, A. C.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S775 - S775
  • [5] Hepatitis C Screening in United States Prisons: Health and Economic Impact on Society
    He, Tianhua
    Roberts, Mark S.
    Grefenstette, John J.
    Chhatwal, Jagpreet
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S972 - S972
  • [6] Immediate versus delayed hepatitis C treatment is cost-saving in the United Kingdom: A pan-genotypic cost-effectiveness analysis
    Dillon, John
    Mitchell, Dominic
    Virabhak, Suchin
    Hermansson, Monika
    Kalabina, Svetlana
    Sanchez, Yuri
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E749 - E750
  • [7] Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China
    Chen, Wen
    Ward, Thomas
    Tan, Mai Ping
    Yan, Jing
    Wang, Peter Feng
    Wygant, Gaild D.
    Gordon, Jason
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (08) : 785 - 795
  • [8] Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study
    Aaron, Alec
    Zhong, Huaiyang
    Hiebert, Lindsey
    Zhuo, Yueran
    Adee, Madeline
    Paraschiv, Angela
    Stratulat, Silvia
    Ward, John W.
    Chhatwal, Jagpreet
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S189 - S197
  • [9] A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States
    Schade, David S.
    Obenshain, S. Scott
    Ramo, Barry
    Eaton, R. Philip
    [J]. AMERICAN JOURNAL OF MEDICINE, 2019, 132 (12): : 1365 - 1367
  • [10] ADDING BOCEPREVIR YIELDS BETTER COST-SAVING FOR CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT IN THAILAND
    Ferrante, S.
    Elbasha, E. H.
    Piratvisuth, T.
    Tanwandee, T.
    Lerdlitruangsin, S.
    Thongsawat, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A677 - A677
12345